Combined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine (Sanofi Pasteur)

N/A

Report date: 2026/05/12 15:11:31

Base Information

Drug NameCombined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine (Sanofi Pasteur)

Drug Alias NameRSV/hMPV/PIV3 vaccine (Sanofi Pasteur)Trivalent RSV-hMPV-PIV3 vaccine (Sanofi Pasteur)SP0291

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsMetapneumovirus infectionsRespiratory Syncytial Virus InfectionsParamyxoviridae Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesSanofi Pasteur

China Registration ClassN/A

Develop Information

Active CompaniesSanofi Sa (Sanofi Ag)Sanofi Pasteur

Inactive CompaniesN/A

Active IndicationsMetapneumovirus infectionsRespiratory Syncytial Virus InfectionsParamyxoviridae Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A